The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones
Abstract
Therapeutic enhancement of fracture healing would help to prevent the occurrence of orthopedic complications such as nonunion and revision surgery. Sclerostin is a negative regulator of bone formation, and treatment with a sclerostin monoclonal antibody (Scl-Ab) results in increased bone formation and bone mass in animal models. Our objective was to investigate the effects of systemic administration of Scl-Ab in two models of fracture healing. In both a closed femoral fracture model in rats and a fibular osteotomy model in cynomolgus monkeys, Scl-Ab significantly increased bone mass and bone strength at the site of fracture. After 10 weeks of healing in nonhuman primates, the fractures in the Scl-Ab group had less callus cartilage and smaller fracture gaps containing more bone and less fibrovascular tissue. These improvements at the fracture site corresponded with improvements in bone formation, bone mass, and bone strength at nonfractured cortical and trabecular sites in both studies. Thus the potent anabolic activity of Scl-Ab throughout the skeleton also was associated with an anabolic effect at the site of fracture. These results support the potential for systemic Scl-Ab administration to enhance fracture healing in patients. © 2011 American Society for Bone and Mineral Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020617 · Cited by 5,016
Bone Histomorphometry : Standardization of Nomenclature, Symbols, and Units
PARFITT, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. А., Malluche, H. H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · Cited by 3,258
HEATLEY, F. W. (1997) · The Journal of Bone and Joint Surgery. British volume · doi:10.1302/0301-620x.79b3.0790511 · Cited by 2,113
Bliuc, D. (2009) · JAMA · doi:10.1001/jama.2009.50 · Cited by 1,699
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
Winkler, D. G. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg599 · Cited by 1,112
Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Li, X., Ominsky, M. S., Niu, Q.-T., Sun, N., Daugherty, B., D'Agostin, D., Kurahara, C., Gao, Y., Cao, J., Gong, J., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080216 · Cited by 936
Self-citationProduction of a standard closed fracture in laboratory animal bone
Bonnarens, F., & Einhorn, T. A. (1984) · Journal of Orthopaedic Research · doi:10.1002/jor.1100020115 · Cited by 888
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
Padhi, D., Jang, G., Stouch, B., Fang, L., & Posvar, E. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.173 · Cited by 786
Li, X., Ominsky, M. S., Warmington, K. S., Morony, S., Gong, J., Cao, J., Gao, Y., Shalhoub, V., Tipton, B., Haldankar, R., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081206 · Cited by 784
Self-citationEnhancement of fracture-healing.
Einhorn, T. A. (1995) · The Journal of Bone & Joint Surgery · doi:10.2106/00004623-199506000-00016 · Cited by 772
Risk of Subsequent Fracture After Low-Trauma Fracture in Men and Women
Center, J. R., Bliuc, D., Nguyen, T. V., & Eisman, J. A. (2007) · JAMA · doi:10.1001/jama.297.4.387 · Cited by 663
Targeting the Wnt/β-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton
Baron, R., & Rawadi, G. (2007) · Endocrinology · doi:10.1210/en.2007-0270 · Cited by 584
Aspenberg, P., Genant, H. K., Johansson, T., Nino, A. J., See, K., Krohn, K., García-Hernández, P. A., Recknor, C. P., Einhorn, T. A., Dalsky, G. P., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090731 · Cited by 513
Ominsky, M. S., Vlasseros, F., Jolette, J., Smith, S. Y., Stouch, B., Doellgast, G., Gong, J., Gao, Y., Cao, J., Graham, K., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.14 · Cited by 414
Self-citationSafety Profile for the Clinical Use of Bone Morphogenetic Proteins in the Spine
Poynton, A. R., & Lane, J. M. (2002) · Spine · doi:10.1097/00007632-200208151-00010 · Cited by 403
Chen, Y., Whetstone, H. C., Lin, A. C., Nadesan, P., Wei, Q., Poon, R., & Alman, B. A. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040249 · Cited by 391
Garrison, K., Donell, S., Ryder, J., Shemilt, I., Mugford, M., Harvey, I., & Song, F. (2007) · Health Technology Assessment · doi:10.3310/hta11300 · Cited by 341
Burr, D. B., Hirano, T., Turner, C. H., Hotchkiss, C., Brommage, R., & Hock, J. M. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.1.157 · Cited by 295
Nakajima, A., Shimoji, N., Shiomi, K., Shimizu, S., Moriya, H., Einhorn, T. A., & Yamazaki, M. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.11.2038 · Cited by 274
Characterization of the Structural Features and Interactions of Sclerostin
Veverka, V., Henry, A. J., Slocombe, P. M., Ventom, A., Mulloy, B., Muskett, F. W., Muzylak, M., Greenslade, K., Moore, A., Zhang, L., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807994200 · Cited by 233
Self-citationThe natural history of sclerosteosis
Hamersma, H., Gardner, J., & Beighton, P. (2003) · Clinical Genetics · doi:10.1034/j.1399-0004.2003.00036.x · Cited by 231
Meyer, R. A., Tsahakis, P. J., Martin, D. F., Banks, D. M., Harrow, M. E., & Kiebzak, G. M. (2001) · Journal of Orthopaedic Research · doi:10.1016/s0736-0266(00)90034-2 · Cited by 228
Bone Regeneration Is Regulated by Wnt Signaling
Kim, J.-B., Leucht, P., Lam, K., Luppen, C., Ten Berge, D., Nusse, R., & Helms, J. A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070802 · Cited by 222
CLINICAL APPLICATIONS OF RECOMBINANT HUMAN BMPS: EARLY EXPERIENCE AND FUTURE DEVELOPMENT
EINHORN, T. A. (2003) · The Journal of Bone and Joint Surgery-American Volume · doi:10.2106/00004623-200300003-00014 · Cited by 194
Manabe, T., Mori, S., Mashiba, T., Kaji, Y., Iwata, K., Komatsubara, S., Seki, A., Sun, Y.-X., & Yamamoto, T. (2007) · Bone · doi:10.1016/j.bone.2007.01.015 · Cited by 131
Use of Bone Morphogenetic Proteins for Musculoskeletal Applications
Mont, M. A., Ragland, P. S., Biggins, B., Friedlaender, G. E., Patel, T. C., Cook, S. D., Etienne, G., Shimmin, A., Kildey, R., Rueger, D. C., et al. (2004) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-200412002-00008 · Cited by 106
Wnt signaling during fracture repair
Secreto, F. J., Hoeppner, L. H., & Westendorf, J. J. (2009) · Current Osteoporosis Reports · doi:10.1007/s11914-009-0012-5 · Cited by 93
Seeherman, H. J., Li, R., Bouxsein, M., Kim, H. J., LI, X. J., Smith-Adaline, E. A., Aiolova, M., & Wozney, J. M. (2006) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-200601000-00018 · Cited by 90
Self-citationChanges in Biochemical Markers after Lower Limb Fractures
Stoffel, K. K., Engler, H., Kuster, M. S., & Riesen, W. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2006.076976 · Cited by 89
Thrombospondin-2 Influences the Proportion of Cartilage and Bone During Fracture Healing
Taylor, D. K., Meganck, J. A., Terkhorn, S. P., Rajani, R., Naik, A., O’Keefe, R. J., Goldstein, S. A., & Hankenson, K. D. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090101 · Cited by 79
Tägil, M., McDonald, M. M., Morse, A., Peacock, L., Mikulec, K., Amanat, N., Godfrey, C., & Little, D. G. (2009) · Bone · doi:10.1016/j.bone.2009.11.009 · Cited by 73
Fox, J., Miller, M. A., Newman, M. K., Recker, R. R., Turner, C. H., & Smith, S. Y. (2007) · Bone · doi:10.1016/j.bone.2007.04.197 · Cited by 70
Self-citationBeta-Catenin-Dependent Wnt Signaling in Mandibular Bone Regeneration
Leucht, P., Kim, J., & Helms, J. A. (2008) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.g.01136 · Cited by 52
Van Buchem disease: lifetime evolution of radioclinical features
Vanhoenacker, F. M. H. M., Balemans, W., Tan, G. J., Dikkers, F. G., de Schepper, A. M., Mathysen, D. G. P., Bernaerts, A., & Hul, W. V. (2003) · Skeletal Radiology · doi:10.1007/s00256-003-0675-4 · Cited by 39
Zuscik, M. J., & O’Keefe, R. J. (2008) · Wiley eBooks · doi:10.1002/9780470623992.ch11 · Cited by 6
Cited by
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
The Osteocyte: An Endocrine Cell … and More
Dallas, S. L., Prideaux, M., & Bonewald, L. F. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1026 · Cited by 1,042
Inflammatory bone loss: pathogenesis and therapeutic intervention
Redlich, K., & Smolen, J. S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3669 · Cited by 830
WNT–β-catenin signalling — a versatile player in kidney injury and repair
Schunk, S. J., Floege, J., Fliser, D., & Speer, T. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00343-w · Cited by 427
Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases
Ke, H. Z., Richards, W. G., Li, X., & Ominsky, M. S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1060 · Cited by 402
Self-citation
Metadata
- Authors
- Ominsky, M. S., Li, C., Li, X., Tan, H. L., Lee, E., Barrero, M., Asuncion, F. J., Dwyer, D., Han, C.-Y., Vlasseros, F., Samadfam, R., Jolette, J., Smith, S. Y., Stolina, M., Lacey, D. L., Simonet, W. S., Paszty, C., Li, G., & Ke, H. Z.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-12-02
- Volume
- 26
- Issue
- 5
- Pages
- 1012-1021
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2040400629
- Cited by
- 264
- References
- 38
- FWCI
- 23.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.